The effects of soy milk consumption on gut microbium community, inflammatory markers, quality of life, symptoms and disease severity in patients with colitits ulcerative

The effects of soy milk consumption on microbiota, inflammatory markers, quality of life, symptoms and disease severity in patients with colitits ulcerative

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181205041859N1

Enrollment

Registered

2019-01-27

Start date

2019-01-05

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colitis ulcerative. Ulcerative colitis, unspecified

Interventions

Intervention 1: Intervention group: daily intake of 200 ml soy milk produced by mandasoy company along with routine treatment for colitis ulcerative patients. Intervention 2: Control group: routine tr

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with colitits ulcerative with moderate severity body mass index between 18.5 and 30

Exclusion criteria

Exclusion criteria: Alteration in type of drugs used for treatment of IBD within last 3 months Having other gut diseases such as related cancers and infections Pregnancy and lactation Antibiotic use during last month Consumption of probiotic products during last month Admitting in hospital during last 3 months History of gut infections during last 3 months Using multivitamin/mineral supplements during last month

Design outcomes

Primary

Measure	Time frame
Gut microbiota community. Timepoint: at the baseline and end of intervention. Method of measurement: real-time PCR method.;Fecal calpotectin. Timepoint: at the baseline and end of intervention. Method of measurement: ELISA.;Fecal lactoferrin. Timepoint: at the baseline and end of intervention. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
Serum hs-CRP levels. Timepoint: at the baseline and end of intervention. Method of measurement: ELISA.;Disease severity for colitis ulcerative. Timepoint: at the baseline and end of intervention. Method of measurement: mayo-score questionnaire for colitis ulcerative.;Disease symptoms such as diarrhea, presence of blood in stool and stomachache. Timepoint: at the baseline and end of trial. Method of measurement: questionnaire.;Serum TNF-a levels. Timepoint: at the baseline and end of trial. Method of measurement: ELISA.;Serum IL-1B levels. Timepoint: at the baseline and end of trial. Method of measurement: ELISA.;Patients quality of life. Timepoint: at the baseline and end of trial. Method of measurement: questionnaire.	—

Measure

Time frame

Serum hs-CRP levels. Timepoint: at the baseline and end of intervention. Method of measurement: ELISA.;Disease severity for colitis ulcerative. Timepoint: at the baseline and end of intervention. Method of measurement: mayo-score questionnaire for colitis ulcerative.;Disease symptoms such as diarrhea, presence of blood in stool and stomachache. Timepoint: at the baseline and end of trial. Method of measurement: questionnaire.;Serum TNF-a levels. Timepoint: at the baseline and end of trial. Method of measurement: ELISA.;Serum IL-1B levels. Timepoint: at the baseline and end of trial. Method of measurement: ELISA.;Patients quality of life. Timepoint: at the baseline and end of trial. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactOmid Sadeghi

Tehran University of Medical Sciences

omidsadeghi69@yahoo.com+98 21 8895 5742

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 27, 2026